Volume 16, Number 5—May 2010
Dispatch
Multihospital Outbreak of Clostridium difficile Infection, Cleveland, Ohio, USA
Robin L.P. Jump, Michelle M. Riggs, Ajay K. Sethi, Michael J. Pultz, Tracie Ellis-Reid, William Riebel, Dale N. Gerding, Robert A. Salata, and Curtis J. Donskey
Table
Clostridium difficile infection rates and healthcare facility characteristics according to respiratory fluoroquinolone on formulary, Cleveland, Ohio, USA, 2006*
| Characteristic | Levofloxacin | Moxifloxacin | Neither† | Total |
|---|---|---|---|---|
| No. hospitals | 13 | 8 | 1 | 22 |
| No. beds, median (IQR) | 232 (108–371) | 361 (217–565) | 1,008 | 316 (125–424) |
| Type of facility | ||||
| Tertiary care | 0 | 2 | 1 | 3 |
| Acute care | 9 | 6 | 0 | 15 |
| Long-term acute care | 4 | 0 | 0 | 4 |
| Hospital system | ||||
| System 1 | 1 | 5 | 0 | 6 |
| System 2 | 11 | 0 | 1 | 12 |
| Neither | 1 | 3 | 0 | 4 |
| No. cases of C. difficile infection | 494 | 569 | 206 | 1,269 |
| Patient-days | 580,893 | 666,719 | 293,833 | 1,541,445 |
| Rate of C. difficile infection/10,000 patient-days, median (IQR) | 8.5 (7.8–9.3) | 8.5 (7.8–9.2) | 7.0 (6.1–8.0) | 8.2 (7.8–8.7) |
*IQR, interquartile range.
†Ciprofloxacin on formulary but no respiratory fluoroquinolone on formulary.
